Irwin Mitchell Advises Eezy Group Ltd On Sale Of Lyphe Group To Tilray Brands

Irwin Mitchell’s Corporate team has advised Eezy Group Ltd on the sale of its subsidiary, Lyphe Group, a UK-based medical cannabis clinic and digital pharmacy platform, to Tilray Brands Inc.

Tilray Brands Inc., a US-headquartered, NASDAQ-listed global lifestyle and consumer packaged goods company, announced the transaction as part of its strategy to strengthen its medical cannabis operations in the UK.

Lyphe Group operates Lyphe Clinic and Lyphe Dispensary, providing end-to-end patient care and dispensing services. To date, Lyphe Dispensary has dispensed approximately 150,000 units, while Lyphe Clinic has treated more than 16,000 patients. The transaction establishes Tilray Medical’s first vertically integrated, patient-centric medical platform in the UK, combining pharmaceutical-grade cannabis cultivation with clinical care and dispensing services.

The Lyphe group of companies was acquired by Eezy Group Ltd in 2023.

The acquisition is expected to support Tilray Brands’ long-term growth strategy and will see the business leverage CC Pharma’s purchasing power to supply medications through the Lyphe platform. Importantly, the deal is a positive signal for the UK medical cannabis sector, reflecting increasing investor confidence in the long‑term growth, maturity and regulatory stability of the market.

This is Tilray’s second UK acquisition in 2026, following its earlier acquisition of BrewDog]

Irwin Mitchell advised Eezy Group Ltd on the transaction, with the corporate legal work led by Kate Sun, Elliott Le-Warde and Claudia Cho.

Kate Sun, Legal Director at Irwin Mitchell, said:

“This transaction reflects the growing interest from international investors in UK businesses operating in the medical cannabis space. We were pleased to support our client in delivering the transaction on time, and it demonstrates Irwin Mitchell’s growing expertise advising on sophisticated deals in this expanding market.”

George Scorsis, Director of Eezy Group Ltd, said:

“We are very happy that the Lyphe Group, our UK-based medical cannabis clinic and digital pharmacy platform, has been acquired by Tilray Brands to establish Tilray Medical’s first vertically integrated patient-centric medical platform in the UK, combining pharmaceutical-grade cannabis cultivation with clinical care and dispensing services. We are proud that Lyphe Dispensary has dispensed approximately 150,000 units to date, while Lyphe Clinic has treated over 16,000 patients.

“We are hugely grateful to the Irwin Mitchell Corporate team, who advised Lyphe’s owners on this sale. The team of Kate Sun, Elliott Le-Warde and Claudia Cho provided timely and down-to-earth advice, remained unflappable in the face of a very tight deadline and were a pleasure to work with. Kate’s leadership and commercially-focused advice, Elliott’s hard work and persistence and Claudia’s attention to detail formed the ideal team for us.”

The transaction further builds on Irwin Mitchell’s expanding role in the legal cannabis sector and follows the recent appointment of Ricardo Geada, Partner in the Regulatory & Compliance Group, who is widely recognised internationally as one of the leading experts on regulatory pathways for medical cannabis in the UK and internationally.